Case Report: Subtherapeutic Vancomycin and Meropenem Concentrations due to Augmented Renal Clearance in a Patient With Intracranial Infection Caused by *Streptococcus intermedius*

Marcus Fransson1†, Anders Helldén2†, Åse Östholm Balkhed3, Dženeta Nezirević Demroth2, Maria Ha3, Mats Haglund4, Peter Milos1, Håkan Hanberger3 and Bertil Kågedal2*

1Department of Neurosurgery and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden, 2Department of Clinical Chemistry and Clinical Pharmacology and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden, 3Department of Infectious Diseases, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden, 4Department of Infectious Diseases, Kalmar County Hospital, Kalmar, Sweden

*Streptococcus intermedius* occasionally causes brain abscesses that can be life-threatening, requiring prompt antibiotic and neurosurgical treatment. The source is often dental, and it may spread to the eye or the brain parenchyma. We report the case of a 34-year-old man with signs of apical periodontitis, endophthalmitis, and multiple brain abscesses caused by *Streptococcus intermedius*. Initial treatment with meropenem and vancomycin was unsuccessful due to subtherapeutic concentrations, despite recommended dosages. Adequate concentrations could be reached only after increasing the dose of meropenem to 16 g/day and vancomycin to 1.5 g × 4. The patient exhibited high creatinine clearance consistent with augmented renal clearance, although iohexol and cystatin C clearances were normal. Plasma free vancomycin clearance followed that of creatinine. A one-day dose of trimethoprim–sulfamethoxazole led to an increase in serum creatinine and a decrease in both creatinine and urea clearances. These results indicate that increased tubular secretion of the drugs was the cause of suboptimal antibiotic treatment. The patient eventually recovered, but his left eye needed enucleation. Our case illustrates that augmented renal clearance can jeopardize the treatment of serious bacterial infections and that high doses of antibiotics are needed to achieve therapeutic concentrations in such cases. The mechanisms for regulation of kidney tubular transporters of creatinine, urea, vancomycin, and meropenem in critically ill patients are discussed.

**Keywords:** suboptimal antibiotic treatment, tubular cell membrane transporters, glomerular filtration rate, augmented renal clearance, vancomycin clearance, iohexol clearance, creatinine clearance, urea clearance

**Abbreviations:** ARC, augmented renal clearance; BSA, body surface area; CNS, central nervous system; CRP, C-reactive protein; CSP, cerebrospinal fluid; OCT, organic cationic transporter; hOCT1, human organic cation transporter-1; hOCT2, human organic cation transporter-2; MATE1, multidrug and toxin extrusion 1; MATE2-K, multidrug and toxin extrusion 2-K; MRI, magnetic resonance imaging; HIV, human immunodeficiency virus; TMP-SMX, trimethoprim–sulfamethoxazole; UT-A1, urea transporter A1; UT-A3, urea transporter A3.
INTRODUCTION

Augmented renal clearance (ARC), defined as a measured creatinine clearance >130 ml/min/1.73 m², is increasingly being recognized in critically ill patients. The condition can lead to subtherapeutic concentrations of renally excreted drugs. The case-patient presented with low serum creatinine concentrations and high creatinine clearance, leading to the diagnosis of ARC. The pathophysiology of ARC is unknown, but high cardiac output, increased tubular creatinine secretion, and hormonal effects have been suggested. ARC may jeopardize the treatment of life-threatening deep bacterial infections with, for instance, members of the Streptococcus anginosus group. We report a patient with S. intermedius infection, endogenous endophthalmitis, and septic embolization to the CNS, arising from a dental infection. Increased drug elimination due to ARC resulted in subtherapeutic antibiotic drug concentrations until high doses were administered. The purpose of this case report is to illustrate the possible causes for rapid elimination of the drugs.

Case Description

A 34-year-old man presented at the emergency room with 1-day history of headache, fever, photosensitivity, and visual impairment. On examination, he was awake but slightly disoriented (Glasgow Coma Scale 14). The following were observed: CRP: 50 mg/L, lumbar puncture: 25 cm H₂O opening pressure (Lee and Lueck, 2014), CSF: white cell count of 7210 × 10⁶/L (6380 × 10⁶/L polymorphonuclear), lactate 8.2 mmol/L, and albumin 880 mg/L. Meningitis was diagnosed and treatment started with meropenem 2 g × 3, acyclovir 800 mg × 3, and betamethasone 8 mg. CT brain showed no sign of abscess or empyema; bilateral diffuse low-density areas were observed in the frontal and temporal lobes, indicating edema (Figure 1A). Methods, reference values, and drug target values are given in Table 1.

His visual impairment worsened, perceiving only light and dark with his left eye. On day 7, MRI with contrast enhancement revealed multiple brain abscesses (Figures 1B–D) and reduced diffusion, indicating ventriculitis. Reduced diffusion was also observed in the retina of the left eye, suggesting abscess and retinal detachment.

The patient was transferred to the university hospital's neurosurgical intensive care unit. CSF cultures were negative for bacteria, fungi, and neurotropic viruses. The QuantiFERON test and the tests for HIV and toxoplasmosis were also negative. The echocardiography indicated no endocarditis or other abnormality. The MRI showed no signs of thrombosis in the jugular vein, indicative of Lemierre's syndrome. The intravitalre and subconjunctival injections of vancomycin and ceftazidime, as well as ocular dexamethasone and cyclopentolate, were administered. A puncture of a subcortical abscess in the right frontal lobe and the placement of an external ventricular drainage were performed.

Day 13 dental examination showed apical periodontitis requiring extraction of one mandibular and three maxillary teeth was identified. Two days later, surgical extirpation of a right frontal cortical abscess was performed. No bacterial growth was seen in cultures, but the material from the brain abscess was sent for 16S rRNA sequencing analysis. S. intermedius was detected and confirmed by PCR analysis. The CSF profiles improved, and day 21 MRI showed slight regression of ventriculitis and some abscesses. Intrathecal antibiotics were discontinued, and the ventricular drainage was removed. Ophthalmological examination showed almost complete retinal detachment with rupture. The eye was beyond help and thus enucleated. The patient was discharged after 6 weeks. Fourteen weeks after admission, the patient still acknowledged cognitive and memory impairments; fatigue; changed sense of smell, sound sensitivity, and photosensitivity; recurrent nightmares; and impaired motor function.

Antibiotic Treatment

Initial treatment was meropenem 2 g × 3 and acyclovir 800 mg × 3. This was changed on day 7 to cefotaxime and metronidazole following the finding of multiple intracerebral abscesses (Table 2). To broaden antibacterial coverage, this was reversed.
### TABLE 1 | Definitions, methods, and reference values.

| Clinical investigation and analysis | Reference intervals, target values | Methods and references |
|-------------------------------------|------------------------------------|------------------------|
| **Clinical evaluation**             |                                    |                        |
| Glasgow Coma Scale (GCS)            | 3–15                               | Definition: The GCS is the summation of scores for eye, verbal, and motor responses. Teasdale and Jennett (1974) and Teasdale and Jennett (1976). The minimum score is 3, which indicates deep coma or a brain dead state. The maximum is 15, which indicates a fully awake patient. |
| Lumbar puncture opening pressure    | 6–25 cm H2O                        | Normal range: Whiteley et al. (2006) and Lee and Lueck (2014). The patient should be placed in lateral decubitus position. |
| Quantiferon                        | Negative                           | Quantiferon is a test for presence of active or latent tuberculosis. Sotgiu et al. (2019). |
| **Cerebrospinal fluid, CSF**        |                                    |                        |
| CSF--albumin                        | <320 mg/L                           | Reference interval: personal information from neurochemistry laboratory, Mölndal. Method: Immunoturbidimetric determination using the cobas c501/701 instruments. Calibrated against ERM-DA470k/IFCC reference material. |
| CSF--lactate                        | <2.1 mmol/L                         | Reference interval: Lindgren et al. (2019). Method: Enzymatic determination using the cobas c501/701 instruments. |
| CSF--WBC                            | 0–6 × 10⁶/L                        | Reference interval: Traditional Method: Cell counts by manual microscopy or phase contrast microscopy using the Fuchs-Rosenthal or Bürker chambers. |
| CSF vancomycin                      | 6–19 mg/L                           | Target value: Albanèse et al. (2000) and Shokouhi and Alavi Darazam (2014). Method: The spectrophotometric homogenous enzyme immune technique used for serum was validated for use as the method for CSF in a correlation study with an HPLC method. Marks et al. (2019). |
| **Plasma or serum and urine**       |                                    |                        |
| P--C-reactive protein               | <10 mg/L                            | Method: Particle enhanced Immunoturbidimetric determination using the instruments cobas c501/701. Calibrated against ERM-DA470k/IFCC reference material. |
| P--Creatinine                       | 61–108 µmol/L                       | Reference interval: Erlandsen and Randers (2018). Method: Enzyme method using cobas c 501/701 instruments from Roche Diagnostics. Creatinine was calibrated using the calibrator for automated systems (C.f.a.s) traceable to the IDMS reference creatinine method. |
| U--Creatinine                       | 5–22 mmol/24 h                      | Reference values: Junge et al. (2004). Method: Enzyme method using cobas c 501/701 instruments from Roche Diagnostics. The method is standardized against the ID/MS calibrator for automated systems (C.f.a.s). The amount excreted per 24 h (mmol/24 h) is calculated as concentration (mmol/L) × volume (L/24 h). |
| P--Iohexol                          |                                    | Method: Iohexol analysis was performed on an Acquity UPLC I-Class UHPLC system coupled with a Xevo TQ-S micro Triple Quadrupole Mass Spectrometer (Waters). Iohexol (Nycomed Amersham AB) and d5-Iohexol, the internal standard, (ALSACHIM SAS) were simultaneously eluted by a BEH C18 column (Waters) using a gradient of 0.1% formic acid in 2 mM ammonium acetate and methanol. Simultaneous peak integration and quantitation for iohexol were achieved automatically using MassLynx Software. |
| P--Cystatin C                       | 0.62–1.04 mg/L                      | Reference interval: Erlandsen and Randers (2018). Method: Particle-enhanced turbidimetric analysis according to principles given by Kyhse-Andersen et al. (1994). Calibrator: C.f.a.s. The method is calibrated against ERM-DA471/IFCCs reference material. Grubb et al. (2014). |
| S--Vancomycin, total                | 15–20 mg/L                          | Target values: Rybak et al. (2009) and Rybak et al. (2020). Method: Spectrophotometric homogenous enzyme immune technique using cobas c 502 instrument from Roche Diagnostics. Calibrator: Preciset TDM I calibrators. |
| S--Vancomycin, free                 | 10.5–14 mg/L                        | (Continued on following page) |
TABLE 1 | (Continued) Definitions, methods, and reference values.

| Clinical investigation and analysis | Reference intervals, target values | Methods and references |
|------------------------------------|-----------------------------------|------------------------|
| P--Meropenem                       | >8 mg/L                           | Target value: Can be estimated as 0.7 × mg/L Sokol (1991), Uchino et al. (2000), Fanos and Cataldi (2001), Shibayama et al. (2007), Klein et al. (2011), Pais et al. (2020) Method: For ultrafiltration of serum, Nanosep Omega PES (Millipore), with a 10 kDa cutoff was used. For chromatographic analysis, we used a Waters Alliance 2695 HPLC system equipped with a Waters bridge column BEH C18 (2.5 μm × 3 mm × 75 mm). Detection was with a photodiode array detector (Waters), and Chromeleon v.7 was used for data collection and analysis |

Clearances

| Creatinine clearance, endogenous | 66–143 | Reference interval: Junge et al. (2004) Method: Urine collection for 12 h. Collection of urine was from midnight (00.00) until 12.00. Plasma creatinine concentrations used for clearance calculations were from early morning the same day Clearance was calculated according to the formula Clcrea (ml/min) = urinary concentration (mmol/L) × urinary volume (L)/serum concentration (mmol/L) × collection time (min). The clearance values were normalized to standard body surface area of 1.73 m² calculated from height and weight according to Dubois and Dubois (1989) |
| Iohexol clearance (GFRiohexol)    | 78–122 ml/min/1.73 m² | Reference values: Bäck et al. (1989) Method: After injection and 4-points measurements iohexol plasma clearance was calculated according to Bröchner-Mortensen (1972). Clearance day 9 was calculated from the dose (67 ml) given at the Department of Radiology and clearance day 14 from the 5 ml dose used in our standard method Krutzén et al. (1984). The clearance values were normalized to standard body surface area of 1.73 m² calculated from height and weight according to Dubois and Dubois (1989) |
| Urea clearance                    | 9.6–60 ml/min/1.73 m² | Reference values: Koch et al. (1980) Method: Urine collection for 12 h. Collection of urine was from midnight (00.00) until 12.00. Plasma urea concentrations used for clearance calculations were from early morning the same day Clearance was calculated according to the formula Clurea (ml/min) = urinary concentration (mmol/L) × urinary volume (L)/serum concentration (mmol/L) × collection time (min). The clearance values were normalized to standard body surface area of 1.73 m² calculated from height and weight according to Dubois and Dubois (1989) |
| Vancomycin clearance from total serum concentrations | 50–157 /p = 10/ or <118 ml/min/1.73 m² from intersection at creatinine clearance of 130 ml/min/1.73 m² | Reference intervals: Rodvold et al. (1988) Clearance of healthy subjects Method: Blood samples for vancomycin concentrations were collected shortly before the dose, immediately after the two hour infusion, and at 3, 4, and 6 hours after the start of the infusion, and as a trough sample before next dose. Vancomycin clearance calculated using the trapezoidal rule and area under the curve (AUC) The clearance values were normalized to standard body surface area of 1.73 m² calculated from height and weight according to Dubois and Dubois (1989) |
| Vancomycin clearance from free serum concentrations | x–y mL/min | Reference intervals: Not available in the literature Method: Vancomycin clearance from free concentrations was obtained and calculated according to the same methods as from total vancomycin in serum The clearance values were normalized to standard body surface area of 1.73 m² calculated from height and weight according to Dubois and Dubois (1989) |
| Cystatin C clearance (eGFRcystatin C) | mL/min/1.73 m² | Reference interval: Ca 15% less than iohexol clearance, see Figure 1A in Grubb et al. (2014) Method: Grubb et al. (2014) estimated clearance from plasma cystatin C was calculated according to the equation eGFR = 130 x Cystatin C^{-1.004} x age^{-0.217} – 7 |
the following day to meropenem and metronidazole, with the addition of intravenous vancomycin, and from day 9, intrathecal vancomycin was administered. On suspicion of toxoplasmosis, he received trimethoprim–sulfamethoxazole (TMP–SMX) on day 11, but this was replaced by rifampicin on day 12. Despite doses ranging from 1.5 g × 3 to 2 g × 4, a stable vancomycin target level of 15–20 mg/L (Rybak et al., 2020) was not achieved until 1.5 g × 4 was given (Table 2). Serum and CSF antibiotic concentrations remained undetectable or subtherapeutic until doses higher than those recommended for meningitis were administered.

**Research Investigations**

Our patient participated in a prospective observational study on the pharmacokinetics of vancomycin in intensive care patients. Vancomycin clearance was determined over a period of 5 days on three occasions, and iohexol clearance on two (Figure 2). The period included the day when TMP–SMX was administered. ARC was diagnosed since creatinine clearance was above 130 ml/min/1.73 m² apart from the days immediately following TMP–SMX treatment. Urea clearance was initially 86% above the upper reference limit (Koch et al., 1980) and followed the same pattern as creatinine clearance (Figure 2). However, iohexol and cystatin C clearances were normal.

Vancomycin clearance calculated from total plasma concentrations was higher than that of iohexol, cystatin C, and creatinine clearances after trimethoprim treatment (Figure 2). The clearance of free vancomycin was even higher, approaching that of creatinine during ARC, indicating that vancomycin underwent both glomerular filtration and tubular secretion. Unfortunately, the total and free vancomycin clearances were not determined each day after TMP–SMX administration, precluding the conclusion regarding the effect of trimethoprim on the systems responsible for the tubular transport of vancomycin.

**DISCUSSION**

**Clinical Observations**

The incidence of brain abscess is 0.3–1.3 per 100,000 people per year, 70% being male with an average age of 34 years (Brouwer et al., 2014a). The pathophysiology of brain abscess varies, with pathogens invading the CNS directly or via the bloodstream. The spread from dental infection is usually direct, causing abscesses in the frontal area. Symptoms are often non-specific, but headache is prominent, and only 50% have fever. Altered consciousness and signs of elevated intracranial pressure may occur. Brain abscesses of dental origin are often caused by mixed infections, for example, anaerobic Gram-positive cocci, and aerobic staphylococci and streptococci (Brouwer et al., 2014b). In this case, *S. intermedius*, a common commensal in the oral cavity, was detected in samples from the abscess material, as in a recent study reporting the predominance of this agent in brain abscesses (Darlow et al., 2020). The broad-spectrum β-lactam antibiotic meropenem, with good CNS penetration, was diagnosed, but despite this, endogenous endophthalmitis was diagnosed a week after admission. A recent case report described how *S. constellatus* of dental origin caused endophthalmitis and brain abscesses (Chheda et al., 2011), and endogenous endophthalmitis caused by *S. intermedius* has been described after routine dental practice (Mali et al., 2015).

The trough values of vancomycin and meropenem were initially far below their suggested therapeutic ranges, although the patient received recommended doses (Table 2), and clearances of creatinine, urea, and free vancomycin were high (Figure 2). The patient’s BMI was 30.9 kg/m² (height 197 cm, weight 120 kg), with a body surface area of 2.55 m², but his serum creatinine the first four days after admission was remarkably low [49, 44, 42, and 41 µmol/L (0.55, 0.49, 0.48, and 0.46 mg/dl)]. Despite his serious infection, sarcopenia was judged not responsible as he was not bedridden and sat in a chair during daytime. On treatment with trimethoprim, a well-known inhibitor of tubular creatinine transport (Berglund et al., 1975), creatinine clearance normalized. Apart from the days immediately following TMP–SMX treatment, creatinine clearance was around 70% higher than iohexol and cystatin C, indicating substantial tubular excretion of creatinine (Figure 2). Total vancomycin clearance was around 45% higher than iohexol and cystatin C clearances, and clearance of free vancomycin was even higher at around 90% of that of creatinine. The high clearance of vancomycin and demand for high doses of both vancomycin and meropenem clearly indicated high tubular secretion of these two drugs. Lonsdale et al. (2013) reported a similar case. This case and our case illustrate the phenomenon of contemporary rapid elimination of vancomycin and meropenem in neurosurgical patients with ARC (Lin Wu et al., 2015).

**Tubular Cell Transport of Creatinine, Urea, Vancomycin, and Meropenem**

The literature regarding the tubular transport of creatinine is extensive (Wang and Kestenbaum, 2018). Creatinine is largely cleared by glomerular filtration, and normally around 10% is actively excreted by tubular transport. In the steady state, the excretion matches muscle production. In humans, creatinine is transported across the basolateral membrane of the proximal tubule by the human organic cation transporter-2 (hOCT2) (Uraakami et al., 2004; Motohashi and Inui, 2013). The antiporter transporters MATE1 and MATE2-K regulate its transport across the apical membrane into the tubular lumen. Trimethoprim is a known inhibitor of this transport system; hence, the temporary reduction in creatinine clearance to normal after trimethoprim treatment clearly shows that tubular creatinine transport was upregulated in this case (Figure 2). Urea is also freely filtered in the glomeruli, but the concentrations along the tubular fluid transport system vary greatly due to resorption of water and removal of urea by transporters in the inner medullary collecting duct cells. The urea transporter UT-A1, at the apical membrane, transports urea from the lumen into the cell, while UT-A3 transports urea across the basolateral membrane to the interstitium. The final elimination of urea in the urine is around 30–50% of the glomerular filtrate in mammals (Klein et al., 2011). Surprisingly, urea clearance was also affected by treatment with trimethoprim in a similar way as...
| Day (days first day with symptoms) | Meropenem dosage | Meropenem trough concentration (mg/L) (>8 mg/L)¹ | Acyclovir 800 mg | Betamethasone 8 mg | Cefotaxime | Metronidazole 1.5 g | Vancomycin dosage | Vancomycin trough concentration (mg/L) (15–20 mg)² | Trimethoprim–sulfamethoxazole (TMP–SMX) (16 mg/ml, 80 mg/ml) | Trimethoprim trough concentration (mg/L) | Sulfamethoxazole trough concentration (mg/L) | Rifampicin 450 mg | Vancomycin intrathecal dosage (mg single dosage) | Vancomycin intrathecal (CSF) trough concentration (mg/L) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 | 2 g x 3 | → → → | → | → | → | → | 1.3 | → | → | → | → | → | → | → | → |
| 4 | 2 g x 4 | → → → | → | → | → | → | → | → | → | → | → | → | → | → | → |
| 5 | 2 g x 4 | → → → | → | → | → | → | → | → | → | → | → | → | → | → | → |
| 6 | 3 g bolus +12 g/dayb | → → → | → | → | → | → | → | → | → | → | → | → | → | → | → |
| 7 | 12 g/dayb | → | → | → | → | → | → | → | → | → | → | → | → | → | → |
| 8 | 16 g/dayb | → | → | → | → | → | → | → | → | → | → | → | → | → | → |
| 9 | → | → | → | → | → | → | → | → | → | → | → | → | → | → | → |
| 10 | → | → | → | → | → | → | → | → | → | → | → | → | → | → | → |
| 11 | → | → | → | → | → | → | → | → | → | → | → | → | → | → | → |
| 12 | → | → | → | → | → | → | → | → | → | → | → | → | → | → | → |
| 13 | → | → | → | → | → | → | → | → | → | → | → | → | → | → | → |
| 14 | → | → | → | → | → | → | → | → | → | → | → | → | → | → | → |
| 15 | → | → | → | → | → | → | → | → | → | → | → | → | → | → | → |
| 16 | → | → | → | → | → | → | → | → | → | → | → | → | → | → | → |
| 17 | → | → | → | → | → | → | → | → | → | → | → | → | → | → | → |
| 18 | → | → | → | → | → | → | → | → | → | → | → | → | → | → | → |
| 19 | → | → | → | → | → | → | → | → | → | → | → | → | → | → | → |
| 20 | → | → | → | → | → | → | → | → | → | → | → | → | → | → | → |
| 21 | → | → | → | → | → | → | → | → | → | → | → | → | → | → | → |

¹Reference values.
²Continuous infusion.
creatinine clearance (Figure 2). The significance of this is unclear and, to our knowledge, has not been reported previously.

Drug transport within the tubular cells is the first fundamental stage in the onset of the nephrotoxic process. Knowledge of these concepts is important for the prevention of iatrogenic kidney damage, particularly in patients with underlying disease receiving concomitant treatment with several potentially nephrotoxic drugs (Fanos and Cataldi, 2001). In experimental models of nephrotoxicity, vancomycin crosses the basolateral membrane of the proximal tubular epithelium via the OCT system (Sokol, 1991). The involvement of MATE1 and MATE2-K proteins in the secretion of vancomycin has yet to be demonstrated (Pais et al., 2020). In our patient, vancomycin and creatinine clearances were simultaneously increased, suggesting that these transporters are also involved; otherwise, intracellular accumulation would have led to toxicity.

In an in vitro study, Shibayama et al. (2007) showed that hOCT1 and hOCT2 transport meropenem but were not able to examine transport across the apical membrane into the lumen. Uchino et al. (2000) reported that Npt1, an inorganic phosphate transporter, participates in the renal secretion of penem antibiotics. While it is known that renal excretion of meropenem is largely through active transport, the mechanism behind the rapid elimination of meropenem in our patient with ARC remains unclear.

**On the Causes of and Factors Contributing to Augmented Renal Clearance**

There is no consensus in the literature regarding the causes of ARC. Recently, Cook and Hatton–Kolpek (2019) addressed the risk factors and potential contributing factors to the emergence of ARC. Chen and Nicolau (2020) published a review on ARC and put forward suggestions on how to identify ARC. There is further no consensus regarding how to define ARC. It should be kept in mind that low–molecular weight endogenous compounds (like creatinine) and drugs (such as vancomycin and meropenem) can be eliminated both by glomerular filtration and tubular secretion. Nevertheless, there is currently a broad consensus in considering the measured creatinine clearance of 130 ml/min/1.73 m² as the lower limit for the diagnosis of ARC. We therefore fully adopt the definition of ARC as creatinine clearance slightly above the upper normal reference limit for GFR, that is, >130 ml/min/1.73 m², as suggested by the Australian team and further advocated by them (Silva et al., 2020) and others (Mahmoud and Shen, 2017; Bilbao-Meseguer et al., 2018; Chen and Nicolau, 2020). Thus, creatinine clearance above this limit indicates ARC, caused by either increased glomerular filtration or tubular secretion. Table 3 shows the clearance rates of our patient both in absolute (ml/min) and normalized (ml/min/1.73 m²) terms. The absolute clearance rates however may just signify high clearance rates due to the big size of the patient and does not by itself indicate ARC. It is therefore confusing that some authors equalize high clearance rates in absolute terms with ARC. Neither can demand for high dosage of drugs by itself define ARC. However, the absolute clearance of each patient is the basis for dosage of the drugs.

One suggested and cherished cause of ARC is an increased cardiac output that would give increased renal blood flow, and thus increased GFR (Sime et al., 2015; Atkinson, 2018). In our patient, an echocardiogram was performed that showed no signs of endocarditis. At this investigation, the cardiac output was considered normal with normal contractility, and there were no signs of organic heart failure. We have measured GFR with the best available method (iohexol plasma clearance), and thus, we exclude the increased cardiac output with increased GFR as the cause of ARC in our patient. The GFR measured by iohexol clearance was quite normal, and the creatinine clearance after trimethoprim treatment decreased to half its value into the area of normal GFR. A similar result was found with urea clearance. We therefore consider the cause of ARC in our patient to be increased tubular secretion. The next question however is whether this is constitutional in our patient or induced during the current period of illness. We reviewed the earlier medical records of our patient and found seven serum creatinine values with mean ± SD of 68.1 ± 13.0 µmol/L during the years 2012–2019. The mean serum creatinine of 44.2 ± 5.7 µmol/L during the present hospital stay was significantly lower than that during the earlier period (p < 0.001). Furthermore, after a follow-up of 16 months, his plasma creatinine was 69 µmol/L, creatinine clearance was 110 ml/min/1.73 m², urea clearance was 48 ml/min/1.73 m², and iohexol clearance was 88 ml/min/1.73 m², that is, quite normal results. It therefore seems that during the stay at neurosurgical unit, he had a period of induced increased tubular secretion of creatinine as the dominant cause of ARC. The conclusion of increased tubular secretions in our patient however does not preclude that increased GFR occurs in other patients. In a recent publication, it was shown that 29 patients had ARC as measured by 6-hour creatinine clearance. Of these, 16 patients had hyperfiltration and 13 had not, as measured by iohexol clearance (Collet et al., 2021). Thus, ARC can be due to...
increased GFR or increased tubular secretion or both. Our study indicates that this may also be true for drugs such as vancomycin and meropenem. To discriminate between these possibilities, employment of a highly standard GFR method is necessary, as well as actual measurement of creatinine or drug clearances that can indicate augmented clearance beyond the patients true GFR.

**CONCLUSION**

This case report describes a 34-year-old man with multiple brain abscesses where the clearances of creatinine, urea, and vancomycin were all increased. High demand for meropenem to reach optimal plasma concentration also indicated increased elimination rate. The increased elimination of these compounds was not due to increased GFR as shown by concomitant measured normal iohexol and cystatin C clearances. We therefore infer that the increased clearances were due to increased tubular secretion. For creatinine, this is proven by the fact that during the study period, temporarily given trimethoprim lowered the clearance of creatinine to normal. High clearance of urea that fell into normal was also found after trimethoprim treatment. However, tubular transport and secretion of urea into the urine are quite different from those of creatinine, and there is no information available in the literature on trimethoprim effects on tubular transporters of urea. This is a new finding and needs to be corroborated in larger studies. Anyhow, urea clearance was higher than normal, and this by itself infers increased excretion into the urine by the tubular system. To our knowledge, there is no reliable information available on human tubular transporters of vancomycin. We have no data on vancomycin clearance the immediate days after trimethoprim dosing, so we cannot evaluate the possible effect of trimethoprim on tubular transport of this drug. However, vancomycin clearance as calculated from non–protein-bound vancomycin was high, above normal GFR and 130 ml/min/1.73 m², set for definition of ARC, and close to the level of creatinine clearance. Thus, our study shows increased tubular secretion of vancomycin, but we cannot indicate the mechanism for its tubular secretion. A limitation of our study is that the clearance rates of meropenem were not actually measured.

We conclude that tubular secretion is responsible for the clearance rates beyond the true normal GFR. Further studies on tubular secretion are needed to understand the mechanisms for increased tubular secretion of drugs in intensive care patients with ARC. Increased clearances of drugs like vancomycin and β-lactam antibiotics may result in life-threatening subtherapeutic antibiotic concentrations. Finally, dose recommendations for renally excreted drugs in ARC patients should be implemented to prevent treatment failure, increased morbidity, and mortality.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article-supplementary material; further inquiries can be directed to the corresponding author.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Regionala etikprövningsnämnden i Linköping c/o Medical Faculty Linköpings universitet 58185 Linköping. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

---

**TABLE 3** | Creatinine, urea, iohexol, cystatin C, and vancomycin (total and free) clearances together with plasma concentrations of creatinine, urea, and cystatin C and excretion of creatinine and urea during the 6 days of clearance studies.

| Vancomycin study day | 1 | 2 | 3 | 4 | 5 | 6 |
|----------------------|---|---|---|---|---|---|
| Day from start of symptoms | 9 | 10 | 11 | 12 | 13 | 14 |
| Plasma creatinine (µmol/L) | 46 | 44 | 44 | 59 | 51 | 43 |
| Creatinine clearance (mL/min) | 305 | 272 | 170 | 199 | 294 |
| Creatinine clearance (mL/min/1.73 m²) | 214 | 190 | 119 | 97 | 206 |
| Urine excretion of creatinine, mmol/24 h | 19.2 | 17.2 | 14.2 | 10.2 | 18.2 |
| Plasma urea (mL/min/L) | 2.1 | 2.6 | 3.5 | 2.5 | 2.4 |
| Urea clearance (ml/min) | 179 | 119 | 71 | 71 | 111 |
| Urea clearance (mL/min/1.73 m²) | 125 | 84 | 50 | 50 | 78 |
| Urine excretion of urea, mmol/24 h | 536 | 447 | 360 | 256 | 384 |
| Iohexol clearance, mL/min | 177a | - | - | - | - |
| Iohexol clearance (mL/min/1.73 m²) | 119a | - | - | - | - |
| Plasma cystatin C (mg/L) | 0.79 | 0.61 | 0.79 | 0.64 | 0.7 |
| Cystatin C clearance (mL/min) | 154 | 206 | 153 | 195 | 174 |
| Cystatin C clearance (mL/min/1.73 m²) | 104 | 139 | 104 | 132 | 119 |
| Vancomycin clearance (ml/min) | 190 | 237 | - | - | - |
| Vancomycin clearance (mL/min/1.73 m²) | 128 | 160 | - | - | - |
| Free vancomycin clearance (mL/min) | 251 | 281 | - | - | - |
| Free vancomycin clearance (mL/min/1.73 m²) | 169 | 190 | - | - | - |

*aCalculated from iohexol given at the Department of Radiology.*

---

Fransson et al. Subtherapeutic Vancomycin and Meropenem Concentrations
AUTHOR CONTRIBUTIONS

BK, DND, HH, and AH provided study concept, design, and project execution. MF and HH included the patient in the study and MF, AH, ÄOB, DND, MH (5th author), and MH (6th author) performed data acquisition and processing. BK drafted the manuscript and included the intellectual content and the revisions from MF, AH, ÄOB, and PM to the final manuscript. All authors revised the manuscript critically for important intellectual content and approved the final version for submission.

REFERENCES

Albanèse, J., Léone, M., Bruguerolle, B., Ayem, M. L., Lacarelle, B., and Martin, C. (2000). Cerebrospinal Fluid Penetration and Pharmacokinetics of Vancomycin Administered by Continuous Infusion to Mechanically Ventilated Patients in an Intensive Care Unit. Antimicrob. Agents Chemother. 44 (5), 1356–1358. doi:10.1128/AAC.44.5.1356-1358.2000
Atkinson, A. J., Jr. (2018). Augmented Renal Clearance. Transl Clin. Pharmacol. 26 (3), 111–114. doi:10.1073/tcpc.2018.26.3.111
Bäck, S. E., Ljungberg, B., Nilsson-Ehle, I., Borgå, O., and Nilsson-Ehle, P. (1989). Age Dependence of Renal Function: Clearance of Iohexol and P-Amino Hippurate in Healthy Males. Scand. J. Clin. Lab. Invest. 49 (7), 641–646. doi:10.1080/03655518909091539
Berglund, F., Killander, J., and Pompeius, R. (1975). Effect of Trimethoprim-Sulfamethoxazole on the Renal Excretion of Creatinine in Man. J. Urol. 114 (6), 802–808. doi:10.1016/s0022-5347(17)67149-0
Bilbao-Meseguer, I., Rodríguez-Gascón, A., Barrasa, H., Isla, A., and Solinis, M. Á. (2018). Augmented Renal Clearance in Critically Ill Patients: A Systematic Review. Clin. Pharmacokinet. 57 (9), 1107–1121. doi:10.1007/s40262-018-0636-7
Bögner-Mortensen, J. (1972). A Simple Method for the Determination of Glomerular Filtration Rate. Scand. J. Clin. Lab. Invest. 30 (3), 271–274. doi:10.3109/03655517209084290
Brouwer, M. C., Coutinho, J. M., and van de Beek, D. (2014). Clinical Characteristics and Outcome of Brain Abscess: Systematic Review and Meta-Analysis. Neurology 82 (9), 806–813. doi:10.1212/WNL.0000000000000172
Brouwer, M. C., Tunkel, A. R., McKhann, G. M., 2nd, and van de Beek, D. (2014). Brain Abscess. N. Engl. J. Med. 371 (5), 447–456. doi:10.1056/NEJMra1301635
Chen, I. H., and Nicolau, D. P. (2020). Augmented Renal Clearance and How to Augment Antiobiotic Dosing. Antibiotics (Basel) 9 (7), 393. doi:10.3390/antibiotics9070393
Chhedra, L. V., Sobol, W. M., Buerk, B. M., and Kurz, P. A. (2011). Endogenous Endothelialmitis with Brain Abscess Causes by Streptococcus Constellatus. Arch. Ophthalmol. 129 (4), 517–518. doi:10.1001/archophthalmol.2011.59
Collet, M., Hijazi, D., Sevrain, P., Barthelemy, R., Labeyrie, M. A., Prie, D., et al. (2021). Evaluation of Glomerular Filtration Rate Using Iohexol Plasma Clearance in Critically Ill Patients with Augmented Renal Creatinine Clearance: A Single-Centre Retrospective Study. Eur. J. Anaesthesiol. 38 (6), 652–658. doi:10.1097/EJA.0000000000001501
Cook, A. M., and Hatton-Kolpek, J. (2019). Augmented Renal Clearance. Pharmacotherapy 39 (3), 346–354. doi:10.1002/phae.22231
Darlow, C. A., McGlashan, N., Kerr, R., Oakley, S., Pretorius, P., Jones, N., et al. (2020). Microbial Aetiology of Brain Abscess in a UK Cohort: Prominent Role of Streptococcus intermedius. J. Infect. 80 (6), 623–629. doi:10.1016/j.jinf.2020.03.011
Dubois, D., and Dubois, E. F. (1989). Nutrition Metabolism Classic - a Formula to Estimate the Approximate Surface-Area if Height and Weight Be Known. 1916. Nutrition 5 (5), 303–311.
Erlandsen, E. J., and Randers, E. (2018). Reference Intervals for Plasma Cystatin C and Plasma Creatinine in Adults Using Methods Traceable to International

FUNDING

Swedish government funding to university hospitals for research, ALF (LIO-887221), and VINNOVA, collaboration platform for innovation of existing antibiotics (PLATINEA, 2018-03340).

ACKNOWLEDGMENTS

The contribution with the pharmacokinetic calculations by Olof Breuer, MD, is greatly appreciated.
Pais, G. M., Liu, J., Zepcan, S., Avedissian, S. N., Rhodes, N. J., Downes, K. J., et al. (2020). Vancomycin-Induced Kidney Injury: Animal Models of Toxicodynamics, Mechanisms of Injury, Human Translation, and Potential Strategies for Prevention. *Pharmacotherapy* 40 (5), 438–454. doi:10.1002/phar.2388

Rodvold, K. A., Blum, R. A., Fischer, J. H., Zokua, H. Z., Rotschafer, J. C., Crossley, K. B., et al. (1988). Vancomycin Pharmacokinetics in Patients with Various Degrees of Renal Function. *Antimicrob. Agents Chemother.* 32 (6), 848–852. doi:10.1128/aac.32.6.848

Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Jr., Craig, W., Billeter, Shokouhi, S., and Alavi Darazam, I. (2014). Determination of Vancomycin Trough Level in Serum and Cerebrospinal Fluid of Patients with Acute Community-Acquired Meningitis: A Prospective Study. *Antibiotics (Basel)* 9 (3), 131. doi:10.3390/antibiotics9030131

Shibayama, T., Sugiyama, D., Kamiyama, E., Tokui, T., Hirota, T., and Ikeda, T. (2020). Therapeutic Monitoring of Meropenem and Piperacillin in Critical Illness: Experience and Recommendations from One Year in Routine Clinical Practice. *Antibiotics (Basel)* 9 (3), 131. doi:10.3390/antibiotics9030131

Shokouhi, S., and Alavi Darazam, I. (2014). Determination of Vancomycin Trough Level in Serum and Cerebrospinal Fluid of Patients with Acute Community-Acquired Meningitis: A Prospective Study. *J. Infect.* 69 (5), 424–429. doi:10.1016/j.jinf.2014.06.010

Silva, C. M., Udy, A. A., and Baptista, J. P. (2020). Urinary Creatinine Clearance and Pharmacokinetics Studies: If We Can Measure it, Why Do We Estimate it? *Antimicrob. Agents Chemother.* 64 (9), e00980-20. doi:10.1128/AAC.00980-20

Sim, F. B., Udy, A. A., and Roberts, J. A. (2015). Augmented Renal Clearance in Critically Ill Patients: Etiology, Definition and Implications for Beta-Lactam Dose Optimization. *Curr. Opin. Pharmacol.* 24, 1–6. doi:10.1016/j.coph.2015.06.002

Sokol, P. P. (1991). Mechanism of Vancomycin Transport in the Kidney: Studies in Rabbit Renal brush Border and Basolateral Membrane Vesicles. *J. Pharmacol. Exp. Ther.* 239 (3), 1283–1287.

Sotgiu, G., Soderi, L., Petruccioli, E., Albérti, S., Piana, A., Petrone, L., et al. (2019). QuantIFERON® TB Gold Plus for the Diagnosis of Tuberculosis: A Systematic Review and Meta-Analysis. *J. Infect.* 79 (5), 444–453. doi:10.1016/j.jinf.2019.08.018

Teasdale, G., and Jennett, B. (1976). Assessment of Coma and Impaired Consciousness. A Practical Scale. *Lancet* 2 (7872), 81–84. doi:10.1016/s0140-6736(74)91639-0

Teasdale, G., and Jennett, B. (1974). Assessment and Prognosis of Coma after Head Injury. *Acta Neurochir.* (Wien) 34 (1–4), 45–55. doi:10.1007/BF01405862

Uchino, H., Tamai, I., Yabuuchi, H., China, K., Miyamoto, K., Takeda, E., et al. (2000). Faropenem Transport across the Renal Epithelial Luminal Membrane via Inorganic Phosphate Transporter Npt1. *Antimicrob. Agents Chemother.* 44 (3), 574–577. doi:10.1128/aac.44.3.574-577.2000

Urakami, Y., Kimura, N., Okuda, M., and Inui, K. (2004). Creatinine Transport by Basolateral Organic Cation Transporter hOCT2 in the Human Kidney. *Pharm. Res.* 21 (6), 976–981. doi:10.1023/b:pham.0000029286.45788.ad

Wang, K., and Kestenbaum, B. (2018). Proximal Tubular Secretory Clearance: A Neglected Partner of Kidney Function. *Clin. J. Am. Soc. Nephrol.* 13 (8), 1291–1296. doi:10.2215/CJN.12001017

Whiteley, W., Al-Shahi, R., Warlow, C. P., Zeidler, M., and Lueck, C. J. (2006). CSF Opening Pressure: Reference Interval and the Effect of Body Mass index. *Neurology* 67 (9), 469–473. doi:10.1212/01.wnl.0000242704.60275.e9

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Fransson, Hélldén, Ostholm Balkhed, Nezirčević Dermoth, Ha, Haglund, Milos, Hanberger and Kågedal. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.